Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...

The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class ...

HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer ...

Iambic, a clinical-stage life science and technology company that uses artificial intelligence to develop medicines has ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end ...

A diagnosis of triple-negative breast cancer is typically made after a biopsy confirms the tumor’s receptor status. Imaging ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sara M. Tolaney, ...